New publication out!

New publication out! Wåhlén et al. have just published the article: Differential impact of lipid raft depletion on platelet-derived growth factor (PDGF)-induced ERK1/2 MAP-kinase, SRC and AKT signaling – ScienceDirect  In the study, they analyzed the co-localization of PDGFR-β and GRB2, PI3K or clathrin, using our Naveni Proximity Ligation Technology. Citation: “For this purpose, NaveniFlex…

Launch News – pY VEGFR2. Navinci is expanding the Naveni PTM product line.

Quantify phospho-VEGFR2 in situ Navinci is expanding the Naveni PTM product line! Quantify phosphorylated VEGFR2 with outstanding signal-to-noise ratio.  Receptor tyrosine kinases (RTKs) are involved in cellular processes and altered phosphorylation states may lead to disturbed signaling pathways, tumor progression, and cancer. Specific tools for quantifying phosphorylation of RTKs in situ have been requested for…

Launch News – NaveniBright kits. Proximity Ligation Assay now with bright-field read out.

LAUNCH NEWS  Navinci is taking the next step to meet the needs of the pathology field. NaveniBright is a new product line with chromogenic readout. The in situ kits are based on our Naveni Proximity Ligation Technology and significantly enhance the chromogenic signal, providing you with stronger and more accurate staining. The assay gives you detailed…

Navinci Diagnostics partners with Ozyme for the distribution of Naveni products in France.

Navinci Diagnostics partners with Ozyme for the distribution of Naveni products in France. Ozyme is a highly skilled partner with deep insight into immunoassays and antibody-related research. Ozyme will make it possible for our French customers to interact with a local distributor with great knowledge within the biotech field. We look forward to working closely with Ozyme;…

Introducing Naveni target-specific assays for phosphorylated RTK’s: EGFR, HER2, PDGFR-beta, MET

Introducing Naveni target-specific assays for phosphorylated RTK’s: EGFR, HER2, PDGFR-beta, MET We are now launching target-specific Naveni in situ proximity ligation assays for phosphorylated receptor tyrosine kinases EGFR, HER2, PDGFR-beta and MET. The assays are based on dual epitope recognition by two primary Navenibodies, that generate an amplified signal when bound in close proximity. This…

Navinci and SciLife enters collaboration: Naveni in situ Proximity Ligation Assay technique will be provided by the SciLifeLab unit Affinity Proteomics Uppsala.

”We are delighted to partner with SciLifeLab and the Affinity Proteomics unit in Uppsala, as this allows the NaveniTM in situ proximity ligation assay technology to support the mission of SciLifeLab to enable life science research in Sweden to provide access to the latest key technologies. This collaboration will significantly benefit our academic customers that…

Navinci partners with Oncolab GmbH, Austria, to supply reagents to their P53 Prions – A novel biomarker test for circulating tumor cells

Navinci partners with Oncolab GmbH, Austria, to supply reagents to their P53 Prions – A novel biomarker test for circulating tumor cells This innovative test from OncoLab (Austria) identifies cancer cells via p53 prions and is based on the proprietary proximity ligation technology from Navinci. The test kits can be used with tissues, cells, and…